Entrar/Registro  
INICIO ENGLISH
 
Gaceta Médica de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Gaceta Médica de México >Año 2001, No. 2


Carrillo-Esper R, Núñez-Monroy FN
Síndrome de respuesta inflamatoria sistémica: nuevos conceptos.
Gac Med Mex 2001; 137 (2)

Idioma: Español
Referencias bibliográficas: 55
Paginas: 127-134
Archivo PDF: 71.30 Kb.


Texto completo




RESUMEN

El síndrome de respuesta inflamatoria sistémica es desencadenado por diferentes disparadores y tiene como finalidad el limitar y revertir la lesión. La intensidad y evolución de la respuesta inflamatoria es determinada por la magnitud de la lesión disparadora y por el balance existente entre la respuesta inflamatoria y la respuesta antiinflamatoria compensadora. La interacción de los diferentes mediadores solubles de la respuestas inflamatoria y antiinflamatoria determinan las siguientes fases evolutivas: a) respuesta inflamatoria local; b) respuesta inflamatoria sistémica; c) respuesta inflamatoria sistémica masiva; d) parálisis inmunológica; e) disonancia inmune. Las últimas tres de no controlarse, amplifican el daño celular, condicionan y perpetúan el proceso infeccioso y llevan al enfermo a disfunción orgánica múltiple. Se han estudiado, en protocolos clínicos y experimentales, el interferón gama y los esteroides como moduladores de la respuesta inflamatoria, sobre todo en sus fases de parálisis y disonancia inmune con resultados promisorios, pero se requieren estudios a gran escala para validar su utilidad.


Palabras clave: Disonancia inmune, Parálisis inmune, Síndrome de Respuesta Inflamatoria Sistémica, Disfunción orgánica múltiple.


REFERENCIAS

  1. Tilney NL, Bailey GL, Morgan AP. Sequential system failure after rupture of abdominal aortic aneurysms: an unsolved problem in postoperative care. Ann Surg 1973;178:117-22.

  2. Baue AE. Multiple, progressive, or sequential systems failure. A syndrome of the 1970's. Arch Surg 1975;110:779-81.

  3. Polk HC Jr, Shields CL. Remote organ failure: a valid sign of occult intraabdominal infection. Surgery 1977;81:310-3.

  4. Fry DE, Pearlstein L, Fulton RL, Polk HC Jr. Multiple organ failure. The role of uncontrolled infection. Arch Surg 1980;115:136-40.

  5. Goris RJ, te Boekhorst TP, Nuytinck JK, Gimbrere JS. Multiple-organ failure. Generalized autodestructive inflammation? Arch Surg 1985;120:1109-15.

  6. Rangel Frausto MS. The natural history of the systemic response syndrome: a prospective study. JAMA 1995;273: 117- 123.

  7. Bone R. Systemic inflammatory response syndrome: a unifyng concept of systemic sepsis and MOF. Alan Fein- Williams & Wilkins. 1997. Ch 1:1:3-11.

  8. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and multiple organ failure, and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:20: 864-74.

  9. Marshal JC, Cook DJ, Christou NC, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995;23:1638-52.

  10. Pinsky MR, Vincent JL, Deviere J, et al. Serum cytokine levels in human septic shock: relation to multiple- system organ failure and mortality. Chest 1993;103:565-75.

  11. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996;24:163-72.

  12. Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995;272: 117-23.

  13. Meduri GU, Kohler G, Headley S, et al. Inflammatory cytokines in the BAL of patients with ARDS: persistent elevation over time predicts a poor outcome. Chest 1995;108:1303-14.

  14. Casey LC. Roles of cytokines in the pathogenesis of cardiopulmonary induced multisystem organ failure. Ann Thorac Surg 1993;56:S92-S96.

  15. Goris RJ. MODS/SIRS: result of an overwhelming inflammatory response? World J Surg 1996;20:418-21.

  16. Ogawa M. Systemic inflammatory response syndrome-a concept for avoiding organ dysfunction induced by a "second attack". Surg Today 1998;28:679-81.

  17. Baue AE, Durbam R, Faist E. Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle? Shock 1998;10:79- 89.

  18. Ziegel EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, et al. Treatment of Gram-negative bacteremia and shock with human anti- serum to a mutant Escherichia coli. N Engl J Med. 1982;307:1225-30.

  19. McCutchan JA, Wolff JL, Ziegler EJ, Braude AI Ineffectiveness of single dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bactereria, Gram-negative infection in patients with prolonged neutropenia Schweiz Med Wochenschr Suppl 1983;165: 695-701.

  20. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993;269:1829-35.

  21. Goldie AS, Fearon KCH, Ross JA, et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 1995;274:172-77.

  22. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin results of a prospective, multicenter, randomized clinical trial. Crit. Care Med 1995;23:994-1006.

  23. McCloskey RV, Straube RC, Sanders C, el al. Treatment of septic shock with human monoclonal antibody HA- 1 A: a randomized double- blind, placebo - controlled trial. Ann Intern Med 1994.1212:1-5.

  24. Fisher CJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin- 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-44.

  25. Abraham E, Wounderink R, Silverman, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor in patients with sepsis syndrome. JAMA 1995;273:934-37.

  26. Remik DG. Applied molecular biology of sepsis. J Crit Care1995;10:198-212.

  27. Cipolle MD, Pasquale NM, Cerra FB. Secondary organ dysfunction: from clinical perspectives to molecular mediators. Crit Care Clin 1993;9:261- 98.

  28. Sigurdsson GH, Christenson JT, Bader el- Rakshy M, et al. Intestinal platelet trapping after traumatic and sepsis shock: an early sign of sepsis and multiorgan failure in critically inpatients? JAMA 1992;20:458-67.

  29. Petrak RA, Balk RA. Prostagiandins, cyclo- oxygenase inhibitors, and thromboxane syntehsis inhibitors in the pathogensis of multiple organ failure. Crit Care Clin 1989;35:303-14.

  30. Dofferboff AS, Vom VJ, de Vries-Hospers HG, et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute- phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992;20:185- 92.

  31. Syrbe U, Meineeke A, Platzer C, et al. lmprovement of monocyte function- a new therapeytic approach? In: Sepsis: current prespectives in pathophysiology and therrapy. New York: Springer Verlag; 1994. p. 473-500.

  32. Mills CD, Caldwell NM, Gann DJ. Evidence of a plama-mediated "window" of immunodeficiency in rats following trauma. J Clin lmmunol 1989;9:139-50.

  33. Platzer C, Meisel C, Vogt K, et al. Up- regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int lmmunol 1995;7:517-23.

  34. Kox WJ, Bone RC, Krausch D, et al. Interferon-gama in the treatment of the compensatory anti-inflammatory response syndrome (CARS)-a new approach: proof of principle. Arch Inter Med 1997;21:389-93.

  35. Randow F, Syrbe U, Meisel C, et al. Mechanisms of endotoxin desensitization: involvement of interleukin-10 and transformation growth factor beta. J Exp Med 1995;181:1887-92.

  36. Livingston DH, Appel SH, Welllhaysen SR, et al. Depressed interferon-gamma production and monocyte HLA-DR expression after severe injury. Arch Surg 1988;123:1309-13.

  37. Lehmann AK, Halstensen A, Sornes S, Rokke O, Waage A. High levels of interleukin 10 in serum are associated with a fatality in meningococcal disease. Infect lmmun 1995;63:2109-12.

  38. Bone RC. Sir lsaac Newton, Sepsis, SIRS and CARS. Crit Care Med 1996;24:1125-1128.

  39. Bone RC. lmmunologic dissonance: a continuing evolution in our understanding of systemic inflammatory response syndrome (SIRS) and the multiple organ dysfuction syndrome. Ann Inter Med 1996;125:680-87.

  40. Szabo G, Kodys K, Miller-Graziano CL. Elevated monocyte interleukin 6 production in immunosuppressed trauma patients. J Clin lmmunol 1991;11:326-35.

  41. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple- system organ failure and mortality. Chest 1993;103:565-75.

  42. Brun-Buisson



>Revistas >Gaceta Médica de México >Año2001, No. 2
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019